Found 84 matching trials
Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants PHASE3 The purpose of this trial is to evaluate the immunogenicity, the safety and...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in Children PHASE3 This study will be conducted in two stages. In the diphtheria, tetanus, per...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults PHASE3 The purpose of this study is to demonstrate, in 18-55 year old adults, the ...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and Toddlers PHASE3 The primary immunogenicity objective is to assess and compare the immunogen...
Show More Learn More & Join Trial
Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine PHASE3 The primary objective was to evaluate the persistence of bactericidal antib...
Show More Location
Alabama Clinical Therapeutics 806 St. Vincent's Drive, Suite 615
Learn More & Join Trial
Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination PHASE3 The purpose/aim of this study is to assess the safety and antibody response...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Understanding the Immune Response to Two Different Meningitis Vaccines PHASE4 The bacterium (germ) Neisseria meningitidis causes meningitis and blood poi...
Show More Location
Oxford Vaccine Group
Treatments Being Tested
MenACWY-CRM conjugate vaccine (Menveo, Novartis) MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis) MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis) 1/5th dose MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis) Polysaccharide (subcutaneously)-conjugate Learn More & Join Trial
Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK 134612 PHASE3 Subjects were previously vaccinated at 11 to 17 years of age. This extensio...
Show More Location
GSK Investigational Site
Learn More & Join Trial
MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age PHASE3 The aim of this study is to determine the immunologic noninferiority of Men...
Show More Location
Alabama Clinical Therapeutics, LLC, Birmington Pediatric Assocaites
Learn More & Join Trial
Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age PHASE3 Safety and immunogenicity of meningococcal ACWY conjugate versus polysaccha...
Show More Location
FUNCEI, French 3085
Learn More & Join Trial